How the Epidemiology of Hodgkin Lymphoma Changed in Debrecen, Hungary
Main Article Content
Abstract
Introduction. Hodgkin lymphoma shows a well-known geographic pattern. Incidence also varies significantly by age, sex, ethnicity and socioeconomic status. These clinical pathological features of the disease are changing. Patients and methods. 715 Hodgkin lymphoma patients’ clinicopathological and treatment data were assessed in a maximum of ten-year periods. The patients were treated at the University of Debrecen, Department of Hematology from 1980 until the end of 2014. Results. The first period (1980-89) contained 193, the second (1990-99) 199, the third (2000-09) 236 and the fourth (2010-14) 87 Hodgkin lymphoma patients. The mean age of the patients were 39, 34.5, 38 and 36.8 years respectively. The male/female ratio was 1.29, 1.23, 1.03 and 0.97 in order. A unimodal age group pattern can be seen in the first and second periods with an incidence peak between 20 and 29 years of age. Bimodal age group pattern was observed in the third and fourth periods with the first incidence peak between 20 and 29 years of age and the second between 50 and 59 years. The incidence of classical mixed cellularity (cMC) histological subtype is decreasing (38%, 49%, 48% and 26%; p < 0.01) while classical nodular sclerosis (cNS) shows an increasing tendency (21%, 28%, 30% and 50%; p < 0.01). The first peak is predominantly caused by the cNS subtype in the third and fourth period, and the second peak caused by cMC subtype in the third and cNS in the fourth period. The number of advanced stage patients (59%) is beyond the early stage patients (41%) in the last observed period. The 5-year overall survival is increasing (64.2%, 84.6%, 87% and 92%). Discussion. The changing patterns can be explained by the altered nature of the disease, changes in immunological features, environmental factors, socioeconomic status and development of diagnostic and therapy methods.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
Cancer Research UK. (n.d.). Retrieved from http://www.cancerresearchuk.org/
Carbone, P. P., Kaplan, H. S., Musshoff, K., Smithers, D. W., & Tubiana, M. (1971). Report of the Committee on Hodgkin’s Disease Staging Classification. Cancer Research, 31(11), 1860–1. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/5121694
Chang, K.-C., Chen, P. C.-H., Jones, D., & Su, I.-J. (2008). Changing patterns in the frequency of Hodgkin lymphoma subtypes and Epstein–Barr virus association in Taiwan. Cancer Science, 99(2), 345–349. doi:10.1111/j.1349-7006.2007.00667.x
Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.-D., … Löffler, M. (2009). Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 27(27), 4548–54. doi:10.1200/JCO.2008.19.8820
European Cancer Observatory - International Agency for Research on Cancer. (n.d.). Retrieved from http://eco.iarc.fr/
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W. W., Comber, H., … al., et. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer (Oxford, England : 1990), 49(6), 1374–403. doi:10.1016/j.ejca.2012.12.027
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., … Bloomfield, C. D. (1999). World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 17(12), 3835–49. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10577857
Hasenclever, D., & Diehl, V. (1998). A prognostic score for advanced Hodgkin’s disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. The New England Journal of Medicine, 339(21), 1506–14. doi:10.1056/NEJM199811193392104
Hjalgrim, H., Smedby, K. E., Rostgaard, K., Molin, D., Hamilton-Dutoit, S., Chang, E. T., … Melbye, M. (2007). Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Research, 67(5), 2382–8. doi:10.1158/0008-5472.CAN-06-3566
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Berthelsen, A. K., Keiding, S., … Specht, L. (2006). Position emission tomography with or without computed tomography in the primary staging of Hodgkin’s lymphoma. Haematologica, 91(4), 482–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16585015
Illés, Á., Keresztes, K., Miltényi, Z., & Molnár, Z. (2004). A Hodgkin-kór hazai epidemiológiai és kezelési adatai - A Hodgkin-kór Munkacsoport beszámolója. Hematológia - Transzfuziológia, 37(3), 155–165.
Kaye, K. M., Izumi, K. M., & Kieff, E. (1993). Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences of the United States of America, 90(19), 9150–4. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8415670
Koch Institute, R., & Centre for Cancer Registry Data, G. (n.d.). German Centre For Cancer Registry Data. Retrieved July 13, 2016, from http://www.krebsdaten.de/Krebs/EN/Home/homepage_node.html
Landgren, O., & Caporaso, N. E. (2007). New Aspects in Descriptive, Etiologic, and Molecular Epidemiology of Hodgkin’s Lymphoma. Hematology/Oncology Clinics of North America, 21(5), 825–840. doi:10.1016/j.hoc.2007.07.001
Lister, T. A., Crowther, D., Sutcliffe, S. B., Glatstein, E., Canellos, G. P., Young, R. C., … Tubiana, M. (1989). Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 7(11), 1630–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2809679
Lukes, R. J., Craver, L. F., Hall, T. C., Rappaport, H., & Ruben, P. (1966). Report of the Nomenclature Committee. Cancer Research, 26(6 Part 1), 1311–1311.
LymphomaInfo.net. (n.d.). Retrieved from www.lymphomainfo.net
Miltényi, Z. (2011). Changing Patterns in the Clinical Pathological Features of Hodgkin Lymphoma: A Report from Debrecen, Hungary Z ofia Miltényi, Z ofia Simon, Edit Páyer, Lászlo Vároczy, Lajos Gergely Adám ona, an Arpád Illés. International Scholarly Research Network ISRN Hematology, 7. doi:10.5402/2011/810708
Salati, M., Cesaretti, M., Macchia, M., Mistiri, M. El, & Federico, M. (2014). Epidemiological Overview of Hodgkin Lymphoma across the Mediterranean Basin. Mediterranean Journal of Hematology and Infectious Diseases, 6(1), e2014048. doi:10.4084/MJHID.2014.048
Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R., … Jaffe, E. S. (2016). The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 127(20), 2375–90. doi:10.1182/blood-2016-01-643569
Tubiana, M., Henry-Amar, M., Carde, P., Burgers, J. M., Hayat, M., Van der Schueren, E., … Thomas, J. (1989). Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin’s disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood, 73(1), 47–56. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2462943
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., … Bloomfield, C. D. (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114(5), 937–51. doi:10.1182/blood-2009-03-209262
Weiss, L. M., Movahed, L. A., Warnke, R. A., & Sklar, J. (2010). Detection of Epstein–Barr Viral Genomes in Reed–Sternberg Cells of Hodgkin’s Disease. http://dx.doi.org/10.1056/NEJM198902233200806.